SCHEMBL5126852

SCHEMBL5126852

Cc1cccc(-c2nc3cccnn3c2-c2ccnc(N)n2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 5/20 0.65
MAPK12 P53778 5/20 0.65
MAPK11 Q15759 5/20 0.65
MAPK14 Q16539 5/20 0.65
CDK2 P24941 2/20 0.44
CDK4 P11802 1/20 0.44
CCNT1 O60563 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK9 P50750 1/20 0.43
IGF1R P08069 1/20 0.42
MAP3K14 Q99558 1/20 0.41
DYRK1A Q13627 1/20 0.40
ADORA1 P30542 1/20 0.40
CSNK1E P49674 1/20 0.40
HSP90AA1 P07900 2/20 0.40
AURKA O14965 1/20 0.40
PRKACA P17612 1/20 0.40
ADORA2A P29274 1/20 0.40
HSP90AB1 P08238 1/20 0.39
PTK2 Q05397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118524 0.84 MAPK14 (0.48) MAPK13MAPK12MAPK11MAPK14CDK2
SCHEMBL5114947 0.83 MAPK14 (0.62) MAPK13MAPK12MAPK11MAPK14AKT1
SCHEMBL5126479 0.79 MAPK13 (0.90) MAPK13MAPK12MAPK11MAPK14DYRK1A
SCHEMBL5114945 0.79 MAPK14 (1.00) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5120095 0.79 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5125496 0.79 MAPK13 (0.88) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5125061 0.76 MAPK13 (0.82) MAPK13MAPK12MAPK11MAPK14PIK3CA
SCHEMBL5119941 0.74 MAPK14 (0.67) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5114397 0.74 MAPK14 (0.70) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5111567 0.73 MAPK14 (0.66) MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 MAPK13 1/4885MAPK12 9/4885MAPK11 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.